CVRx, Inc.

CVRx sells primarily to hospitals and implanting centers that treat heart failure patients and perform Barostim procedures. The company’s commercial focus is on high-volume cardiology centers, where adoption can scale through physician training and referral networks. Key users and influencers include heart failure specialists, interventional and general cardiologists, advanced practice providers, electrophysiologists, vascular surgeons, and cardiothoracic surgeons. In the U.S., reimbursement from CMS is an important part of the buying decision because it affects hospital willingness to adopt the therapy and patient access. In Europe, hospitals and distributors are the main commercial counterparties, with local pricing and channel mix influencing uptake.

CVRx’s near-term strategy is to expand its U.S. direct sales force and deepen penetration at high-volume cardiology centers. The company is also investing in physician education, KOL development, referral network education, and direct-to-consumer marketing to improve awareness and conversion. On the product side, management is focused on continued technological advancement of Barostim while maintaining the current commercial focus on HFrEF. Longer term, CVRx wants to broaden Barostim’s addressable market by pursuing additional indications such as other forms of heart failure, hypertension, and arrhythmias, which would require further clinical evidence and regulatory approvals. This strategy is designed to increase procedure volume, strengthen reimbursement-supported adoption, and reduce dependence on a single indication over time.